Gastrointestinal endoscopy · 2013
Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uchino Rie, Isayama Hiroyuki, Tsujino Takeshi, Sasahira Naoki, Ito Yukiko, Matsubara Saburo, Takahara Naminatsu, Arizumi Toshihiko, Toda Nobuo, Mohri Dai, Togawa Osamu, Yagioka Hiroshi, Yanagihara Yoshitsugu, Nakajima Katsuyoshi, Akiyama Dai, Hamada Tsuyoshi, Miyabayashi Koji, Mizuno Suguru, Kawakubo Kazumichi, Kogure Hirofumi, Sasaki Takashi, Yamamoto Natsuyo, Nakai Yousuke, Hirano Kenji, Tada Minoru, Koike Kazuhiko
Аннотация
BACKGROUND: Our previous study suggested that a combination of ulinastatin and risperidone reduced post-ERCP pancreatitis (PEP) compared with ulinastatin alone.
OBJECTIVE: The aim of this study was to evaluate the efficacy of risperidone alone for prevention of PEP.
DESIGN: A multicenter, randomized, placebo-controlled, double-blind clinical trial.
SETTING: Two academic hospitals and 5 referral hospitals in Tokyo and Saitama, Japan.
PATIENTS: Patients undergoing therapeutic or interventional-diagnostic ERCP.
INTERVENTION: The patients were randomized to receive 2 mg of oral risperidone or oral placebo at 0.5 to 2 hours before ERCP.
MAIN OUTCOME MEASUREMENTS: The primary endpoint was the incidence of PEP. Secondary endpoints were the incidence of hyperenzymemia and enzyme levels (amylase, pancreatic amylase, lipase). Risk factors for PEP were evaluated.
RESULTS: We initially enrolled 500 patients in the study (250 in the risperidone group and 250 in the placebo group), but 17 (11 in the risperidone and 6 in the placebo group) were excluded after randomization. PEP developed in 24 patients (10.0%) in the risperidone group and 21 patients (8.6%) in the placebo group (P = .587). Serum amylase levels at 3 hours after ERCP were lower in the risperidone group (P = .007 in a single test of hypothesis, significance removed by Bonferroni correction for multiple testing). In multivariate analysis, a small papilla of Vater, total procedure time ≥40 minutes, and stenosis of the intrahepatic duct were significantly associated with PEP.
LIMITATIONS: Multiplicity of study centers and a relatively wide time range of drug administration time.
CONCLUSION: Risperidone did not show a benefit in prevention of PEP in this trial. (
CLINICAL TRIAL REGISTRATION NUMBER: NCT000004592.).
OBJECTIVE: The aim of this study was to evaluate the efficacy of risperidone alone for prevention of PEP.
DESIGN: A multicenter, randomized, placebo-controlled, double-blind clinical trial.
SETTING: Two academic hospitals and 5 referral hospitals in Tokyo and Saitama, Japan.
PATIENTS: Patients undergoing therapeutic or interventional-diagnostic ERCP.
INTERVENTION: The patients were randomized to receive 2 mg of oral risperidone or oral placebo at 0.5 to 2 hours before ERCP.
MAIN OUTCOME MEASUREMENTS: The primary endpoint was the incidence of PEP. Secondary endpoints were the incidence of hyperenzymemia and enzyme levels (amylase, pancreatic amylase, lipase). Risk factors for PEP were evaluated.
RESULTS: We initially enrolled 500 patients in the study (250 in the risperidone group and 250 in the placebo group), but 17 (11 in the risperidone and 6 in the placebo group) were excluded after randomization. PEP developed in 24 patients (10.0%) in the risperidone group and 21 patients (8.6%) in the placebo group (P = .587). Serum amylase levels at 3 hours after ERCP were lower in the risperidone group (P = .007 in a single test of hypothesis, significance removed by Bonferroni correction for multiple testing). In multivariate analysis, a small papilla of Vater, total procedure time ≥40 minutes, and stenosis of the intrahepatic duct were significantly associated with PEP.
LIMITATIONS: Multiplicity of study centers and a relatively wide time range of drug administration time.
CONCLUSION: Risperidone did not show a benefit in prevention of PEP in this trial. (
CLINICAL TRIAL REGISTRATION NUMBER: NCT000004592.).